A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Key facts
- Where
- Boston, Bowling Green, Camp Hill, Charleston, Charlotte, Cleveland, Columbia, Dallas, Durham, Farmington, Fountain Valley, Fremont, Frisco, Hialeah, Indianapolis, Los Angeles, Louisville, Marriottsville, Mayfield Heights, Miami, Milwaukee, Murfreesboro, Nashville, North Little Rock, Omaha, Phoenix, Portsmouth, Rogers, Sandy Springs, Santa Monica, Skokie, South Jordan, Spokane, St Louis, Sugarloaf, Tampa, and Troy, United StatesSee the 42 sites
- Phase
- Phase 2
Where in United States
- Beth Israel Deaconess Medical CenterBoston, United StatesNo longer taking part
- Equity Medical Bowling GreenBowling Green, United StatesNo longer taking part
- DermDox Centers for DermatologyCamp Hill, United StatesNo longer taking part
- Medical University of South CarolinaCharleston, United StatesNo longer taking part
- Darst DermatologyCharlotte, United StatesNo longer taking part
- Dermatology Specialists of CharlotteCharlotte, United StatesNo longer taking part
- University Hospitals Cleveland Medical Center*Cleveland, United StatesNo longer taking part
- Columbia Dermatology & AestheticsColumbia, United StatesNo longer taking part
- Modern Research AssociatesDallas, United StatesNo longer taking part
- Duke University Medical CenterDurham, United StatesNo longer taking part
- University of ConnecticutFarmington, United StatesNo longer taking part
- First Oc Dermatology Research IncFountain Valley, United StatesNo longer taking part
- Center For Dermatology Clinical Research, Inc.Fremont, United StatesNo longer taking part
- North Texas Clinical ResearchFrisco, United StatesNo longer taking part
- Direct Helpers Research CenterHialeah, United StatesNo longer taking part
- Dawes Fretzin Clinical Research Group, LLCIndianapolis, United StatesNo longer taking part
- Dermatology Research AssociatesLos Angeles, United StatesNo longer taking part
- Derm Research LLCLouisville, United StatesNo longer taking part
- Care Access-MarriottsvilleMarriottsville, United StatesNo longer taking part
- Apex Clinical Research CenterMayfield Heights, United StatesNo longer taking part
- Skin Research of South FloridaMiami, United StatesNo longer taking part
- University of MiamiMiami, United StatesNo longer taking part
- Medical College of WisconsinMilwaukee, United StatesNo longer taking part
- International Clinical Research - Tennessee (IC Research)Murfreesboro, United StatesNo longer taking part
- Advanced Research ExpertsNashville, United StatesNo longer taking part
- Arkansas Research Trials, LLCNorth Little Rock, United StatesNo longer taking part
- Skin Specialists, P.COmaha, United StatesNo longer taking part
- Medical Dermatology SpecialistsPhoenix, United StatesNo longer taking part
- Saguaro Dermatology Associates, LLC - Probity - PPDSPhoenix, United StatesNo longer taking part
- ActivMed Practices & Research, Inc.Portsmouth, United StatesNo longer taking part
- Northwest Arkansas Clinical Trials CenterRogers, United StatesNo longer taking part
- Advanced Medical Research, PC.Sandy Springs, United StatesNo longer taking part
- Dermatology Institute and Skin Care CenterSanta Monica, United StatesNo longer taking part
- NorthShore Medical Group Dermatology SkokieSkokie, United StatesNo longer taking part
- Jordan Valley Dermatology CenterSouth Jordan, United StatesNo longer taking part
- Dermatology Specialists of SpokaneSpokane, United StatesNo longer taking part
- Washington University School of MedicineSt Louis, United StatesNo longer taking part
- DermDox Dermatology CentersSugarloaf, United StatesNo longer taking part
- Alliance Clinical Research of TampaTampa, United StatesNo longer taking part
- ForCare Clinical ResearchTampa, United StatesNo longer taking part
- Olympian Clinical ResearchTampa, United StatesNo longer taking part
- Revival Research Institute - TroyTroy, United StatesNo longer taking part
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT06046729EU 2023-505608-43-00
- Record updated
- 21 August 2026
- Original description
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.Read full original descriptionShow less
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
Inclusion: Have a diagnosis of HS for at least 12 months; Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III; Have an (abscess plus inflammatory nodule) count of at least 5; Agree to use topical antiseptics daily; Had an inadequate response or intolerance to a 28-day course of oral antibiotics.
Exclusion: Have had surgical treatment for HS in the last 4 weeks before randomization; Have an active skin disease or condition, that could interfere with the assessment of HS; Have a current or recent acute, active infection; Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening; Have more than 20 draining fistulae; Are immunocompromised.